| Company Name: |
cjbscvictory |
| Tel: |
13348960310 13348960310 |
| Email: |
3003867561@qq.com |
GSK3395879 manufacturers
- GSK3395879
-
- $2120.00
-
2026-04-20
- CAS:2215852-91-6
- Purity:
- Supply Ability: 10g
|
| | GSK3395879 Basic information |
| Product Name: | GSK3395879 | | Synonyms: | GSK3395879;GSK-3395879,GSK3395879;Benzonitrile, 4-[[(3S,4R)-1-[[2-cyano-4-(trifluoromethyl)phenyl]sulfonyl]-4-hydroxy-4-(hydroxymethyl)-3-pyrrolidinyl]oxy]-2-fluoro- | | CAS: | 2215852-91-6 | | MF: | C20H15F4N3O5S | | MW: | 485.41 | | EINECS: | | | Product Categories: | | | Mol File: | 2215852-91-6.mol |  |
| | GSK3395879 Chemical Properties |
| Boiling point | 665.8±65.0 °C(Predicted) | | density | 1+-.0.1 g/cm3(Predicted) | | pka | 12.57±0.40(Predicted) |
| | GSK3395879 Usage And Synthesis |
| Description | GSK3395879 is a potent, selective and orally active TRPV4 inhibitor (IC50 = 1 nM), GSK3395879 demonstrated the ability to inhibit TRPV4-mediated pulmonary edema in an in vivo rat model. GSK3395879 is a tool for studying the biology of TRPV4 and an advanced lead for identifying new heart failure medicines. | | Uses | GSK3395879 is a selective and orally bioavailable transient receptor potential vanilloid-4 (TRPV4) antagonist with an IC50 of 1 nM for hTRPV4[1]. | | References | [1] Brnardic EJ, et al. Discovery of Pyrrolidine Sulfonamides as Selective and Orally Bioavailable Antagonists of Transient Receptor Potential Vanilloid-4 (TRPV4). J Med Chem. 2018 Nov 8;61(21):9738-9755. DOI:10.1021/acs.jmedchem.8b01317 |
| | GSK3395879 Preparation Products And Raw materials |
|